
CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study
BURLINGTON, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- CoreMap today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to extend the INvENI clinical study into the U.S. This study is …